InvestorsHub Logo

Theo

12/06/17 5:22 PM

#1661 RE: Giovanni #1660

SA piece after Madrigal's phase IIb sucess:

NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196
Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor
Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading.
Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)


I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH.
From CNAT Website:

We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease and potentially provide treatment options in multiple areas of liver disease.

(as well as other organs eventually).

Theo

12/06/17 5:34 PM

#1662 RE: Giovanni #1660

I believe the next potential Novartis payment will be a "milestone" payment of which the criteria used to determine its implementation has never been clarified or identified... to the best of my knowledge anyway.

It would be nice to wake some morning with a PR stating that they have, in fact, issued a check for some benchmark reached...

I added today below 3.97. There was no whole-sale sell-off which suggests to me that confused/nervous money exited after MDGL's phase IIb success without really understanding the implications.